- Home
- INCY vs CLH Comparison
INCY vs CLH Comparison
Compare INCY & CLH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- CLH
- Stock Information
- Founded
- INCY 1991
- CLH 1980
- Country
- INCY United States
- CLH United States
- Employees
- INCY N/A
- CLH N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- CLH Environmental Services
- Sector
- INCY Health Care
- CLH Industrials
- Exchange
- INCY Nasdaq
- CLH Nasdaq
- Market Cap
- INCY 17.0B
- CLH 12.7B
- IPO Year
- INCY 1993
- CLH 1987
- Fundamental
- Price
- INCY $105.02
- CLH $206.29
- Analyst Decision
- INCY Buy
- CLH Buy
- Analyst Count
- INCY 19
- CLH 10
- Target Price
- INCY $89.19
- CLH $252.90
- AVG Volume (30 Days)
- INCY 2.7M
- CLH 720.2K
- Earning Date
- INCY 10-28-2025
- CLH 10-29-2025
- Dividend Yield
- INCY N/A
- CLH N/A
- EPS Growth
- INCY 3878.02
- CLH N/A
- EPS
- INCY 5.90
- CLH 7.20
- Revenue
- INCY $4,813,105,000.00
- CLH $5,962,257,000.00
- Revenue This Year
- INCY $19.33
- CLH $2.95
- Revenue Next Year
- INCY $10.47
- CLH $4.16
- P/E Ratio
- INCY $17.83
- CLH $28.50
- Revenue Growth
- INCY 18.09
- CLH 2.85
- 52 Week Low
- INCY $53.56
- CLH $178.29
- 52 Week High
- INCY $106.47
- CLH $265.72
- Technical
- Relative Strength Index (RSI)
- INCY 78.36
- CLH 29.84
- Support Level
- INCY $91.16
- CLH $205.84
- Resistance Level
- INCY $106.47
- CLH $248.07
- Average True Range (ATR)
- INCY 4.10
- CLH 6.39
- MACD
- INCY 1.57
- CLH -3.19
- Stochastic Oscillator
- INCY 93.55
- CLH 6.47
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About CLH Clean Harbors Inc.
Clean Harbors Inc is an environmental and industrial services provider. It provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. The company generates the majority of its revenues from the Environmental Services segment.